Parent	Approved Consent Group(s)	PI Name		dies listed are retained. https://www.nhlbiwgs.org/proposalresource/1217	TOPMed Accession #	Date manuscript approval request submitted/s ent	Response (Exar "waiting on stu granted", etc.)
		Braxton D.		Please email draft (doesn't need to be final) to Rhea Cosentino			Draft sent to PI,
Amish	HMB-IRB-MDS	Mitchell		(rcosenti@som.umaryland.edu)	phs000956	17-Sep-20	Instructions (Co
	HMB-IRB,DS-CVD-			https://www2.cscc.unc.edu/aric/sites/default/files/public/listings/Manu		1.0.1.20	
ARIC	IRB	Eric Boerwinkle	laha	script_Procedures%20UPDATED%205-18-15.pdf	phs001211	1-Oct-20	P&P approval gi
CCAF	GRU-IRB	Mina Chung	John Barnard	Please email to chungm@ccf.org and barnarj@ccf.org	phs001189	17-Sep-20	Draft sent to Pl
CHS	HMB-NPU-MDS	Bruce Psaty	Russell Tracy	draft to the CHS Publications Committee for review via the CHS website (https://chs-nhlbi.org/node/add/non-standard). The draft should have a mature author list and include the correct acknowledgements. For consortium-based papers and meta- or pooled-analyses, manuscripts are granted an expedited review (7-10 days) in which the submitting author serves as the primary reviewer who assures that: (1) CHS is correctly represented, (2) genetics exclusions are adequately described, (3) the inclusion or exclusion of the minority cohort is properly addressed, and (4) that the content of the paper matches the original proposal. Alternately, TOPMed papers that use CHS data that are without a CHS co-author (i.e., those in which no CHS author accepted an invitation to participate), should be submitted directly to ecterry@uw.edu. The cover note should include contact information for the lead author, the full authorship listing, and an abstract, and the four assurances listed above. In addition, the cover note should address the following points: - The paper derives from the: TOPMed omnibus- Where the analysis was performed- The name of the analyst- That it is an ancillary study (Psaty, AS#238)- The study type is: ancillary, meta-analysis/pooled analysis- Manuscript key words: TOPMed, [phenotype]- Confirm that ancillary studies are credited and that CHS is correctly represented- Indicate whether you or any member of the WG intend to patent any process, aspect, or outcome of these analyses- Indicate whether analyses involve a for-profit corporation- Confirm that the paper includes the required genetic exclusions statement: "CHS analyses were limited to participants with available DNA who consented to genetic studies."- Indicate whether CMS data is		5-Oct-20	P&P approval g
			Donald W.	DIVA WHO CONSENTED TO BENETIC STUDIES INDICATE WHETHER CIVIS DATA IS	pu2001368	5-UCT-20	
DHS	NPU,HMB-IRB-COL- NPU	Nicholette Palmer	Bowden	Manuscripts should be sent to Nichole Allred (nallred@wakehealth.edu).	phs001412	17-Sep-20	Draft sent to PI, Instructions (Co
FHS	HMB-IRB-NPU- MDS,HMB-IRB-MDS	Vasan S. Ramachandran	L. Adrienne Cupples	Papers should be sent to Ann Walsh (walshac@nhlbi.nih.gov) and Karen Mutalik (kmutalik@bu.edu).	phs000974	17-Sep-20	Draft sent to PI, Instructions (Co

amples: "no response received", tudy P&P committee", "approval .)

PI, study co-authors & individual in Col G). See Email to co-authors.

granted; letter attached.

PIs as instructed (Col G).

granted; letter attached.

PI, study co-authors & individual in Col G)

PI, study co-authors & individual in Col G)

Parent Study short name	Approved Consent Group(s)	PI Name	Co-PI Name	Instructions for how to obtain study-specific manuscript review	TOPMed Accession #	Date manuscript approval request submitted/s ent	Response (Exar "waiting on stu granted", etc.)
	HMB-IRB-MDS,HMB-	Vasan S.		Papers should be sent to Ann Walsh (walshac@nhlbi.nih.gov) and Karen			Draft sent to PI,
FHS	IRB-NPU-MDS	Ramachandran	Dan Levy	Mutalik (kmutalik@bu.edu).	phs000974	17-Sep-20	Instructions (Co
GeneSTAR	DS-CVD-IRB-NPU- MDS	Rasika Mathias		We have a Steering Committee in place for all GeneSTAR publications. You may initiate this Steering Committee Review by emailing the TOPMed Study PI Dr. Rasika Mathias (rmathias@jhmi.edu)	phs001218	5-Oct-20	Steering Comm attached letter.
GENOA	DS-ASC-RF-NPU	Sharon Kardia	Jennifer Smith	GENOA does not have a formal review process. However, we request that the GENOA co-author(s) included on the paper approve the manuscript prior to submission.	phs001345	21-Sep-20	Draft sent to Pl attached email
HyperGEN	GRU-IRB,DS-CVD- IRB-RD	Donna K Arnett		Manuscripts should be sent to steven.claas@uky.edu.	phs001293	21-Sep-20	PI, study co-aut (Col G).
JHS	DS-FDO-IRB,HMB- IRB-NPU,HMB- IRB,DS-FDO-IRB-	Adolfo Correa	Laura Raffield	https://www.jacksonheartstudy.org/Research/Publications#submitmanus cript	phs000964	13-Oct-20	P&P approval g comments p.2 a
MESA	HMB-NPU,HMB	Jerome Rotter	Stephen Rich	Manuscripts (penultimate drafts) need to be sent to the MESA Genetics P&P Committee for review (typically for appropriate statement of MESA and its funding sources) with contact Jane Fulcher (genpp@uw.edu)	phs001416	17-Sep-20	P&P submitted,
Samoan	GRU-IRB-PUB-COL- NPU-GSO	Stephen McGarvey		If data from the Samoan study are used, then contact the overall PI, Stephen McGarvey at Brown University. Email is above, or phone 401-863- 1354	phs000972	24-Sep-20	Approval by PI, PI, study co-aut
	HMB-IRB-NPU,HMB-	Charles		Any TOPMed paper using WHI data and/or including WHI co-authors needs to be reviewed by the WHI P&P committee. To initiate the review, email the (penultimate) manuscript to WHI P&P asking for review of the			
WHI	IRB	Kooperberg		paper, cc-ing Charles Kooperberg .	phs001237	9-Oct-20	P&P approval g
Additional s	tudies used in Analyse I	es, but were not i	ncluded in do			1	
CFS				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs000954	18-Sep-20	Approval by PI, PI, study co-aut
COPDGene				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs000951	2-Oct-20	P&P approval g
GenSalt				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs001217	17-Sep-20	No response re
GOLDN				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs001359	21-Sep-20	Approval by PI, PI, study co-aut (Col G-HyperGE
HVH- AFGen				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs000993	20-Sep-20	Approval by PI, PI, study co-aut
HVH-VTE				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous- review	phs000993	8-Oct-20	Approval by PI, PI, study co-aut

```
amples: "no response received",
tudy P&P committee", "approval
.)
```

PI, study co-authors & individual in Col G)

mittee approval received; see er.

PIs, study co-authors approved, see ail.

uthors & individual in Instructions

granted; letter attached. Minor 2 addressed.

ed, awaiting approval

I, see attached letter. Draft sent to uthors, see Email to co-authors.

granted; letter attached.

I, see attached letter. Draft sent to uthors, see Email to co-authors.

granted; letter attached.

received. See Email to co-authors. I, see attached letter. Draft sent to uthors & individual in Instructions GEN).

I, see attached letter. Draft sent to uthors, see Email to co-authors.

I, see attached letter. Draft sent to uthors, see Email to co-authors.

-	Approved Consent Group(s)	PI Name	Co-PI Name	Instructions for how to obtain study-specific manuscript review	TOPMed Accession #	Date manuscript approval request submitted/s ent	Response (Exa "waiting on stu granted", etc.)
				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous-			
MGH				review	phs001062	17-Sep-20	No response re
				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous-			
Partners				review	phs001024	17-Sep-20	No response re
				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous-			Approval by PI,
San Antonic	Family Study			review	phs001215	18-Sep-20	PI, study co-aut
				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous-			
VAFAR				review	phs000997	17-Sep-20	No response re
				none listed: https://www.nhlbiwgs.org/studies-requiring-simultaneous-			
VU_AF				review	phs001032	17-Sep-20	No response re

xamples: "no response received", study P&P committee", "approval c.)

received. See Email to co-authors.

received. See Email to co-authors. PI, see attached letter. Draft sent to authors, see Email to co-authors.

received. See Email to co-authors.

received. See Email to co-authors.